

Double Plasma Molecular Adsorption System

A recommended artificial liver system in CMA Liver Failure Guidelines

DPMAS

Product Parameters	BS330 Disposable Plasma Bilirubin Adsorption Column	HA330-II Disposable Hemoperfusion Cartridge
Adsorbent volume(ml)	330	330
Adsorbent material	Polystyrene divinylbenzene anion exchange resin	Double Crosslinked Styrene Divinylbenzene Copolymers
Housing material	Polypropylene	Polycarbonate
Sterilization method	Moist heat sterilization	Irradiation Sterilization
Unit Package	280mm(L)×105mm(W)×108mm(H)	285±2mm(L)*117±2mm(W)*108±2mm(H)

*Contraindications, Warnings and Precautions refer to Instructions For Use.

JAFRON - Global manufacturer and supplier of adsorption columns



Jafron Headquarters



CE



ISO 9001



EN ISO 13485

References

- [1] Xia, Q. et al. A single-center experience of non-bioartificial liver support systems among Chinese patients with liver failure. *Int. J. Artif. Organs* 2014; 37, 442–454
- [2] Yao, J. et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. *J. Clin. Apher* 2019; 1–7. doi:10.1002/jca.21690
- [3] Wan, Y. M. et al. Therapeutic plasma exchange versus double plasma molecular adsorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by enterocavir: A prospective study. *J. Clin. Apher* 2017; 32, 453–461.
- [4] Rong, J. et al. Fructus Psoraleae-induced liver injury and treatment with two artificial liver support systems: a case series study. *Ther. Apher. Dial* 2019; doi:10.1111/1744-9987.13438
- [5] Li, M. et al. Part of plasmapheresis with plasma filtration adsorption combined with continuous hemodiafiltration in the treatment of severe acute liver failure. *Exp. Ther. Med* 2016; 12, 2582–2584.
- [6] Ma, K. wang et al. Synergistic effects of polymer adsorbents on the performance of bilirubin hemoperfusion. *J. Biomater. Sci. Polym. Ed* 2017; 28, 2053–2065
- [7] Ma, Y. et al. Safety and Efficacy of Regional Citrate Anticoagulation during Plasma Adsorption Plus Plasma Exchange Therapy for Patients with Acute-on-Chronic Liver Failure: A Pilot Study. *Blood Purif* 2019; 610041
- [8] Su, R. et al. Preparation and adsorption properties of novel porous microspheres with different concentrations of Bilirubin. *Blood Purif* 2016; 42, 104–110
- [9] Tan, Y. et al. Therapeutic plasma exchange and a double plasma molecular adsorption system in the treatment of thyroid storm with severe liver injury: A case report. *World J. Clin.* 2019; Cases 7, 1184–1190
- [10] Jiajia Chen. et al. A clinical study on the treatment of severe hepatitis by a combined artificial liver. *Hepato-Gastroenterology* 2012; doi:10.5754/hge12025
- [11] Sharma. et al. Hepatitis A virus-induced severe hemolysis complicated by severe Glucose-6-Phosphate Dehydrogenase deficiency. *Indian J. Crit. Care Med* 2018; 22, 670–673
- [12] Chen, G. et al. Effects of dual plasma molecular adsorption system on liver function, electrolytes, inflammation, and immunity in patients with chronic severe hepatitis. *J. Clin. Lab. Anal* 2019; 1–6. doi:10.1002/jcla.22926
- [13] Li, L. et al. Transjugular Intrahepatic Portosystemic Shunt Combined with Haemoperfusion in an End-stage Renal Disease Patient with Liver Cirrhosis-related Refractory Portal Hypertensive Variceal Bleeding: A Case Report. *WIMJ Open* 2011; 64, 452–455.
- [14] Li, M. qin et al. Efficacy of Various Combined Blood Purification Techniques for Treating Patients with Non-viral Acute Liver Failure. *Cell Biochem. Biophys* 2014; 68, 571–575.
- [15] Li, M. Combined use of non-biological artificial liver treatments for patients with acute liver failure complicated by multiple organ dysfunction syndrome. *World J. Emerg Med* 2014; 5, 214.
- [16] Li, M. et al. Clinical observation on the treatment of acute liver failure by combined non-biological artificial liver. *Exp. Ther. Med* 2016; 12, 3873–3876 (2016).

Comprehensive Therapy for Hepatopathy



CY-DPMAS-01-10-2021-EN



JAFRON BIOMEDICAL CO., LTD.

Address: No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China.

Tel: +86 (756) 3689708

E-mail: overseatrade@jafron.com


Website: en.jafron.com

(For Internal Use)


Double Plasma Molecular Adsorption System (DPMAS) provides a **new solution for liver disease**. It adsorbs bilirubin, removes inflammatory mediators, eases inflammation and immune responses as well as considerably relieves the clinical symptoms and eventually improves the long-term prognosis of patients.

Adsorption Therapy Applications^{Δ[2-5]}

According to clinical practices, DPMAS therapy can be applied in the listed conditions.




Therapy Operation Modes^Δ



BS330 adsorbs bilirubin, bile acid.




HA330-II broad-spectrum adsorbs toxins such as inflammatory mediators, bilirubin, etc.^[3]



Clinical Data


Remove Bilirubin and Bile Acid



PE: Plasma exchange; HF: Hemofiltration. Compared with pre-treatment, *p<0.05,**p<0.01^[4]

Clinical studies showed that DPMAS could remove Bilirubin^[1-16] and Bile Acid^[3-4,10], and have comparable effect as therapeutic plasma exchange.^[4]


Remove Inflammatory Mediators and Improve Hemodynamics



IL-6, Interleukin-6; TNF-α, Tumor necrosis factor-α; hsCRP, High sensitivity C reactive protein. Compared with before treatment, *p<0.05^[12]

DPMAS(HA330-II) could remove the inflammatory mediators such as IL-6^[3,12], TNF-α^[12], CRP^[3,12] and PCT^[3], and balance the ammonia^[11] level, thus to improve the clinical symptoms.

Improve Organ Function



Compared with before treatment, *p<0.05^[5]

DPMAS(HA330-II) could improve liver function by improving the levels of AST^[2-5,10-11], ALT^[2-5,9-12,16], ALP^[9], GGT^[9], and other indexes.

^ΔFor detailed information, please visit en.jafron.com.